Clinical performance and robustness evaluation of plasma amyloid-β

Further evidence is needed to support the use of plasma amyloid β (Aβ) biomarkers as Alzheimer's disease prescreening tools. This study evaluated the clinical performance and robustness of plasma AβData were collected from 333 BioFINDER and 121 Alzheimer's Disease Neuroimaging Initiative study participants. Risk and predictive values versus percentile of plasma AβElecsys plasma AβImplementing plasma AβPlasma Aβ